Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Pretargeted Immuno-PET with TF2 and 68Ga-IMP-288 in MTC
NCT01730638Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Jan 2013
- Primary completion
- Dec 2016
- Modality
- Bispecific Antibodies, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of hMN-14 × m734, 68 Ga-IMP-288 in medullary thyroid carcinoma (MTC), sponsored by CHU de Nantes. Started Jan 2013; status: completed.
02
Drugs
hMN-14 × m73468 Ga-IMP-288
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT01730638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730638.